Abstract
Endocrine disorders are known to cause cardiovascular disturbances that have clinical implications. Acromegaly causes enlargement of the heart, premature coronary artery disease (CAD), heart failure, hypertension, intraventricular conduction defects, and cardiac arrhythmias may require management by a cardiologist. Mild hypertension occurs in more than 50 % of patients. Rarely acromegalic cardiomyopathy occurs. The defect in the myocardium causes arrhythmias, which weaken the myocardial force that leads to heart failure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
ACCORD Risk-Factor Control in Type 2 Diabetes the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.
ACCORD Study Group The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
Adler JT, Meyer-Rochow GY, Chen H, et al. Pheochromocytoma: current approaches and future directions. Oncologist. 2008;13:779–93.
Andrews MA, O’Malley PG. Diabetes overtreatment in elderly individuals: risky business in need of better management. JAMA. 2014;311(22):2326–7.
Biondi B, Palmieri EA, Lombardi G, et al. Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab. 2002;87:968–74.
Bravo EL. Pheochromocytoma. Curr Ther Endocrinol Metab. 1997;6:195–7.
Castillo JG, Filsoufi F, Rahmanian PB, et al. Early and late results of valvular surgery for carcinoid heart disease. J Am Coll Cardiol. 2008;51:1507–9.
Choi YH, Chung JH, Bae SW, et al. Severe coronary artery spasm can be associated with hyperthyroidism. Coronary Artery Dis. 2005;16:135–9.
Connolly HM, Nishimura RA, Smith HC, et al. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol. 1995;25:410–6.
Connolly HM, Schaff HV, Mullany CJ, et al. Surgical management of left-sided carcinoid heart disease. Circulation. 2001;104:I36–40.
Demers LM, Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13:3–126.
Dorr M, Wolff B, Robinson DM, et al. The association of thyroid function with cardiac mass and left ventricular hypertrophy. J Clin Endocrinol Metab. 2005;90:673–7.
DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551–62. DREAM.
Fiebrich H-B, Brouwers AH, Kerstens MN. 6-[F-18]Fluoro-L-Dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 2009;94:3922–30.
Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresistance an unintended consequence of enteric coating aspirin. Circulation. 2013;127:377–85.
Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.
Hanley AJ, Zinman B, Sheridan P, et al. Effect of rosiglitazone and ramipril on b-cell function in people with impaired glucose tolerance or impaired fasting glucose. Diab Care. 2010;33:608–13.
Kanto JH. Current status of labetalol, the first alpha- and beta-blocking agent. Int J Clin Pharmacol Ther Toxicol. 1985;23:617–28.
Khan MG. Clinical trials. In: Cardiac drug therapy. Philadelphia, PA: WB Saunders/Elsevier; 2003. p. 502.
Khan MG. Hypertension. In: Heart disease diagnosis and therapy, 2nd ed. New York: Humana Press/Springer; 2005. p. 340.
Khan MG. Hypertension. In: Encyclopedia of heart diseases. New York: Springer; 2011. p. 556.
Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth. 2002;16:359–69.
Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116:1725–35.
Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501–9.
Lehmann HU, Hochrein H, Witt E, et al. Hemodynamic effects of calcium antagonists: review. Hypertension. 1983;5:II66–73.
Mannelli M. Management and treatment of pheochromocytomas and paragangliomas. Ann N Y Acad Sci. 2006;1073:405–16.
Murphy MB, Lewis PJ, Kohner E, et al. Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow up. Lancet. 1982;2:1293–5.
Nathan DM. Navigating the choices for diabetes prevention. NEJM. 2010;362:1533–5.
Procopiou M, Finney H, Akker SA, et al. Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors. Eur J Endocrinol. 2009;161:131–40.
Proye C, Thevenin D, Cecat P, et al. Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients. Surgery. 1989;106:1149–54.
RECORD Study Team, Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes a multicentre, randomised, open-label trial. Lancet. 2009;373:2125–35.
Rodondi N, Aujesky D, Vittinghoff E, et al. Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis. Am J Med. 2006;119:541–51.
Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011;364:542–50.
Roumie CL, Greevy RA, Carlos G, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311(22):2288–96.
Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228–38.
The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. BMJ. 1998;317:713–20.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Khan, M.G. (2015). Endocrine Heart Diseases. In: Cardiac Drug Therapy. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-962-4_18
Download citation
DOI: https://doi.org/10.1007/978-1-61779-962-4_18
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-961-7
Online ISBN: 978-1-61779-962-4
eBook Packages: MedicineMedicine (R0)